High tumor mutational burden
Marengo’s invikafusp alfa shows promising monotherapy activity in PD-1 resistant gastrointestinal cancers
Invikafusp alfa; Marengo Therapeutics; PD-1 resistant tumors; Gastrointestinal cancers; Colorectal cancer; TMB-H; MSI-H; Immunotherapy; ESMO 2025; FDA Fast Track designation